Johnson & Johnson vs ELI LILLY & Co, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where JNJ and LLY diverge most: on ev/ebitda, JNJ reads 326.4 and LLY reads 2200.4; on revenue growth, JNJ reads +8.1% and LLY reads +47.4%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | JNJ | LLY |
|---|---|---|
| Price | $256.46 | $1148.86 |
| Market cap | $625.8B | $1.08T |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +22.8% |
| P/E | 29.8 | 40.8 |
| P/B | 7.36 | 34.68 |
| P/S | 6.39 | 14.97 |
| EV/EBITDA | 326.4 | 2200.4 |
| Revenue growth | +8.1% | +47.4% |
| Gross margin | 68.2% | — |
| Net margin | 21.5% | 35.0% |
| Return on equity | 24.8% | 81.0% |
| Return on assets | 10.5% | 21.7% |
| FCF yield | 3.5% | 1.9% |
| Dividend yield | 2.0% | 0.5% |
| Debt / equity | 0.58 | 1.39 |
| Current ratio | 1.09 | 1.50 |
| Altman Z (solvency) | 4.95 | 7.16 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.